Skip to Main Content
Table 2—

Comparison of glucose and insulin response to a test meal and nateglinide, glibenclamide, or placebo in the 15 patients with MODY3 patients

NateglinideP1GlibenclamideP2PlaceboP3
Plasma glucose (mmol/l)       
    Fasting 7.9 (5.6) NS 7.8 (2.2) NS 7.8 (2.7) NS 
    Peak 9.8 (8.9) 0.031 11.5 (6.6) 0.031 12.7 (7.2) <0.0001 
    140 min 9.1 (7.8) 0.029 7.1 (9.2) 0.0001 10.4 (9.9) 0.0038 
    170 min 7.3 (7.0) 0.004 6.3 (8.0)* 0.0005 8.3 (10.3) 0.0018 
    260 min 6.4 (4.9) 0.006 5.5 (3.9) 0.0002 7.6 (7.8) 0.0124 
    ΔPeak 3.3 (2.9) 0.031 4.5 (3.9) NS 4.7 (3.5) <0.0001 
    Δ140 min 1.85 (2.85) 0.026 −0.3 (5.6) 0.0019 2.7 (4.7) 0.0008 
    AUC140 min§ 101 (294) 0.041 186 (391) 0.027 250 (348) <0.0001 
Urine glucose (mmol/l)       
    Fasting 0 (20.4) NS 1.4 (37.1) NS (21.3) NS 
    140 min 15.4 (59.8) NS 42.7 (74.0) NS 33.0 (97.0) NS (0.06) 
    260 min 3.8 (52.8) NS 10.4 (70.1) NS 46.0 (67.9) NS 
    Serum insulin (mU/l)       
    Fasting 5.8 (4.3) NS 5.2 (4.5) NS 6.0 (5.4) NS 
    Peak 47.0 (26.0) 0.023 80.4 (71.7) 0.0002 33.7 (24.9) <0.001 
    AUC140 min§ 2,912 (1,668) 0.024 3,253 (3,888) 0.0002 1,652 (2,150) 0.002 
Hypoglycemia (n) 0/15 0.030 6/15 0.030 0/15 NS 
NateglinideP1GlibenclamideP2PlaceboP3
Plasma glucose (mmol/l)       
    Fasting 7.9 (5.6) NS 7.8 (2.2) NS 7.8 (2.7) NS 
    Peak 9.8 (8.9) 0.031 11.5 (6.6) 0.031 12.7 (7.2) <0.0001 
    140 min 9.1 (7.8) 0.029 7.1 (9.2) 0.0001 10.4 (9.9) 0.0038 
    170 min 7.3 (7.0) 0.004 6.3 (8.0)* 0.0005 8.3 (10.3) 0.0018 
    260 min 6.4 (4.9) 0.006 5.5 (3.9) 0.0002 7.6 (7.8) 0.0124 
    ΔPeak 3.3 (2.9) 0.031 4.5 (3.9) NS 4.7 (3.5) <0.0001 
    Δ140 min 1.85 (2.85) 0.026 −0.3 (5.6) 0.0019 2.7 (4.7) 0.0008 
    AUC140 min§ 101 (294) 0.041 186 (391) 0.027 250 (348) <0.0001 
Urine glucose (mmol/l)       
    Fasting 0 (20.4) NS 1.4 (37.1) NS (21.3) NS 
    140 min 15.4 (59.8) NS 42.7 (74.0) NS 33.0 (97.0) NS (0.06) 
    260 min 3.8 (52.8) NS 10.4 (70.1) NS 46.0 (67.9) NS 
    Serum insulin (mU/l)       
    Fasting 5.8 (4.3) NS 5.2 (4.5) NS 6.0 (5.4) NS 
    Peak 47.0 (26.0) 0.023 80.4 (71.7) 0.0002 33.7 (24.9) <0.001 
    AUC140 min§ 2,912 (1,668) 0.024 3,253 (3,888) 0.0002 1,652 (2,150) 0.002 
Hypoglycemia (n) 0/15 0.030 6/15 0.030 0/15 NS 

Data are median (interquartile range). Each patient participated in the test three times receiving in double-blind random order: 1) placebo at time 0 min and 30 mg nateglinide at 20 min, 2) 1.25 mg glibenclamide at 0 min and placebo at 20 min, or 3) placebo at both 0 and 20 min. The subjects ingested a test meal between 30 and 45 min. P1: nateglinide vs. glibenclamide visits; P2: glibenclamide vs. placebo visits; P3: nateglinide vs. placebo visits.

*

n = 14 and

n = 12 due to hypoglycemia.

Difference between peak or 140 min glucose and fasting glucose.

§

AUC, incremental area under the curve during 0–140 min.

Plasma glucose ≤3.5 mmol/l.

Close Modal

or Create an Account

Close Modal
Close Modal